Factors associated with treatment of women with osteoporosis or osteopenia from a national survey

BMC Women's Health

Volumn 12, Issue , 2012, Pages

  Meadows, Eric S ^a   Mitchell, Beth D ^a   Bolge, Susan C ^b   Johnston, Joseph A ^a   Col, Nananda F ^c,d  

^a ELI LILLY AND COMPANY   (United States)

^b Centocor Ortho Biotech   (United States)

^c UNIVERSITY OF NEW ENGLAND   (United States)

^d Shared Decision Making Resources   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BONE DENSITOMETRY; COMORBIDITY; DISEASE ASSOCIATION; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; UNITED STATES; CLINICAL PRACTICE; ESTROGEN THERAPY; METABOLIC BONE DISEASE; MIDDLE AGED; PHOTON ABSORPTIOMETRY; STATISTICS;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH SURVEYS; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84855419697     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-12-1     Document Type: Article

References (35)

1. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis. N Engl J Med 1992, 327:620-627. 10.1056/NEJM199208273270908, 1640955.
2. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94:646-650.
3. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006, 194(2 Suppl):S3-S11.
4. National Osteoporosis Foundation America's bone health: The state of osteoporosis and low bone mass. National Osteoporosis Foundation., http://www.nof.org/aboutosteoporosis/bonebasics/whybonehealth
5. O'Neill TW, Roy DK. How many people develop fractures with what outcome?. Best Pract Res Clin Rheumatol 2005, 19:879-895. 10.1016/j.berh.2005.06.003, 16301185.
6. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000, 54(Suppl 1):58-63.
7. Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006, 194(2 Suppl):S12-S23.
8. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med 2006, 119(4 Suppl 1):S3-S11.
9. University of Michigan Health System Osteoporosis: Prevention and Treatment 2005, Ann Arbor, University of Michigan Health System, University of Michigan Health System.
10. Kaiser Permanente Care Management Institute Osteoporosis/Fracture Prevention Clinical Practice Guidelines 2008, Oakland, Kaiser Permanente Care Management Institute, Kaiser Permanente Care Management Institute.
11. Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens DK, . Clinical Efficacy Assessment Subcommittee of the American College of Physicians Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008, 149:404-415. Clinical Efficacy Assessment Subcommittee of the American College of Physicians.
12. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, . AACE Osteoporosis Task Force American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition with Selected Updates for 2003. Endocr Pract 2003, 9:545-564. AACE Osteoporosis Task Force.
13. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001, 44:1496-1503.
14. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008, 19:429-435. 10.1007/s00198-007-0544-4, 2267486, 18292977.
15. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397. 10.1007/s00198-007-0543-5, 2267485, 18292978.
16. Kuehn BM. New tool measures 10-year fracture risk. JAMA 2008, 299:1651-1652. 10.1001/jama.299.14.1651, 18398069.
17. National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation 2008, Washington, DC, National Osteoporosis Foundation, National Osteoporosis Foundation.
18. Dawson-Hughes B, Tosteson AN, Melton LJ, Baim S, Favus MJ, Khosla S, Lindsay RL, . National Osteoporosis Foundation Guide Committee Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008, 19:449-458. 10.1007/s00198-008-0559-5, 18292975, National Osteoporosis Foundation Guide Committee.
19. Tosteson AN, Melton LJ, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, . National Osteoporosis Foundation Guide Committee Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008, 19:437-447. 10.1007/s00198-007-0550-6, 2729707, 18292976, National Osteoporosis Foundation Guide Committee.
20. Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KW. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med 2008, 23(11):1815-1821. 10.1007/s11606-008-0772-0, 2585659, 18787907.
21. National Health and Wellness Survey, 2007, US 2007, Princeton, Consumer Health Sciences.
22. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12 Health Survey 2005, Lincoln, RI: QualityMetric Incorporated.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8, 3558716.
24. Dequeker J, Boonen S, Aerssens J, Westhovens R. Inverse relationship osteoarthritis-osteoporosis: what is the evidence? What are the consequences?. Br J Rheumatol 1996, 35:813-8. 10.1093/rheumatology/35.9.813, 8810662.
25. Dai LY. The relationship between osteoarthritis and osteoporosis in the spine. Clin Rheumatol 1998, 17:44-6. 10.1007/BF01450957, 9586678.
26. Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, Avorn J. Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 2005, 80:194-202. 10.4065/80.2.194, 15704774.
27. Brennan RM, Wactawski-Wende J, Crespo CJ, Dmochowski J. Factors associated with treatment initiation after osteoporosis screening. Am J Epidemiol 2004, 160:475-483. 10.1093/aje/kwh245, 15321845.
28. Mudano AS, Casebeer L, Patino F, Allison JJ, Weissman NW, Kiefe CI, Person S, Gilbert D, Saag KG. Racial disparities in osteoporosis prevention in a managed care population. South Med J 2003, 96:445-451. 10.1097/01.SMJ.0000053918.93363.B0, 12911182.
29. Neuner JM, Zhang X, Sparapani R, Laud PW, Nattinger AB. Racial and socioeconomic disparities in bone density testing before and after hip fracture. J Gen Intern Med 2007, 22:1239-1245. 10.1007/s11606-007-0217-1, 2219762, 17594131.
30. Demeter S, Leslie WD, Lix L, MacWilliam L, Finlayson GS, Reed M. The effect of socioeconomic status on bone density testing in a public health-care system. Osteoporos Int 2007, 18:153-158. 10.1007/s00198-006-0212-0, 17019518.
31. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002, 46:3136-3142. 10.1002/art.10613, 12483716.
32. Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int 2010, 21:1427-36. 10.1007/s00198-009-1079-7, 2895897, 19798459.
33. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, Spettell CM, Weissman NW, Wilke S, Saag KG. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005, 52:2485-2494. 10.1002/art.21194, 16052570.
34. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001, 286:2815-2822. 10.1001/jama.286.22.2815, 11735756.
35. Jones TJ, Petrella RJ, Crilly R. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol 2008, 35:1865-1873.